๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Peking Union Medical College Hospital276 Beijing Tiantan Hospital214 Cancer Institute and Hospital, Chinese Academy of Medical Sciences197 AstraZeneca183 Peking University People's Hospital158
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Beijing

5484 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Deep Cervical Lymphatic Venous Anastomosis in the Treatment of Alzheimer's Disease (CLEAN-AD Registry)
NCT07058129Alzheimers Disease
Beijing Tiantan Hospital
Observational
814
Beijing
2025-07-30
Not yet open
A Multicenter, Prospective, Non-Interventional Real-World Study of Iparomlimab and Tuvonralimab Injection (QL1706) in the Treatment of Locally Advanced or Metastatic Solid Tumors
NCT07046780Solid Tumor Cancer, Metastatic Solid Tumors, Locally Advanced
PENG YUAN
Observational
90
Beijing
2025-07-30
Recruiting
TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer
NCT07044908RAS/BRAF Wild Type Colorectal Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1/2
72
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Meizhou, Shantou, Nanning
2025-07-30
Not yet open
The Combination of Upadacitinib and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia
NCT07064889Immune Thrombocytopenia
Peking University People's Hospital
Phase 2
132
Beijing
2025-07-30
Active, closed
A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH)
NCT07073417Obesity, Weight Management
Hangzhou Sciwind Biosciences Co., Ltd.
Phase 2
163
Beijing
2025-07-28
Recruiting
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
NCT06911502Follicular Lymphoma
Celgene
Phase 3
400
Beijing, Fuzhou Fujian, Guangzhou, Harbin, Wuhan, Changsha, Hohhot, Suzhou
2025-07-28
Not yet open
Phase I/II Study of SCTB39G in Advanced Solid Tumours
NCT07077252Advanced Malignant Solid Tumor
Sinocelltech Ltd.
Phase 1/2
30
Beijing
2025-07-28
By invitation
Ureteroscopy Combined With Negative Pressure Sheath Treatment of Kidney Stones
NCT06938113Kidney Calculi
Peking University First Hospital
Observational
115
Beijing
2025-07-28
Recruiting
Repetitive Transcranial Magnetic Stimulation and Postoperative Neurocognitive Recovery
NCT06482749Older Patients, Cognitive Impairment, Repetitive Transcranial Magnetic Stimulation, Delayed Neurocognitive Recovery
Peking University First Hospital
Not applicable
568
Beijing, Shenzhen, Xi'an
2025-07-28
Recruiting
Novel Allogenic CD19-targeting CAR-ฮณฮดT Cell Therapy (QH103E) in r/r NHL
NCT06838832Non-hodgkin Lymphoma,B Cell
Chinese PLA General Hospital
Phase 1/2
30
Beijing
2025-07-27
Recruiting
TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
NCT07047365HER2-positive Advanced Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
416
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Shenzhen
2025-07-25
Recruiting
Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis
NCT07039578Primary Light-Chain Amyloidosis
Keymed Biosciences Co.Ltd
Phase 2
90
Beijing, Tianjin
2025-07-25
Recruiting
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
NCT07066657Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer
ArriVent BioPharma, Inc.
Phase 1
572
Beijing, Chongqing, Zhejiang, Heilongjiang, Zhengzhou, Wuhan, Changsha, Shandong
2025-07-25
Recruiting
A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity
NCT06974851Bstructive Sleep Apnea (OSA) and Obesity
Fujian Shengdi Pharmaceutical Co., Ltd.
Phase 3
140
Beijing
2025-07-25
Recruiting
Efficacy and Safety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal Insulin
NCT07060456Type 2 Diabetes
Fujian Shengdi Pharmaceutical Co., Ltd.
Phase 3
300
Beijing
2025-07-25
Recruiting
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
NCT07037433Atherosclerotic Cardiovascular Disease, Overweight, Obesity
Amgen
Phase 3
12,800
Bengbu, Beijing, Guangzhou, Huizhou, Yulin, Qinhuangdao, Shijiazhuang, Harbin
2025-07-25
Recruiting
Short-term Bactericidal Effect of Contezolid in MAC-PD
NCT07084402Mycobacterium Avium Complex Pulmonary Disease
Bin Cao
Phase 4
188
Beijing, Nanchang
2025-07-24
Recruiting
a Safety, Tolerability, and Pharmacokinetic Trial of Multiple Subcutaneous Injections of B1344 Injection in Patients With Nonalcoholic Fatty Liver Disease๏ผˆNAFLD๏ผ‰
NCT07128797NAFLD (Non-alcoholic Fatty Liver Disease), NASH (Nonalcoholic Steatohepatitis)
Tasly Biopharmaceuticals Co., Ltd.
Phase 1
32
Beijing, Guangzhou, Datong, Tianjin, Wenzhou
2025-07-24
Recruiting
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
NCT06807268Eczema
Pfizer
Phase 3
150
Beijing, Shenzhen, Changsha, Nanchang, Shanghai, Hangzhou
2025-07-24
Recruiting
Short-term Antibiotic Therapy in Mycobacterium Avium Complex Pulmonary Disease
NCT07213765Mycobacterium Avium Complex Pulmonary Disease
Bin Cao
Phase 4
188
Hefei, Beijing, Guangzhou, Nanchang, Shanghai
2025-07-24
Recruiting
Prevention of Recurrence With Cordyceps Sinensis in Mycobacterium Avium Complex Pulmonary Disease
NCT07174076Mycobacterium Avium Complex Pulmonary Disease
Bin Cao
Phase 4
300
Hefei, Beijing, Guangzhou, Nanchang, Shanghai
2025-07-24
Recruiting
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
NCT06758401Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
Pfizer
Phase 3
714
Hefei, Beijing, Fuzhou, Guangzhou, Huizhou, Nanning, Harbin, Luoyang
2025-07-23
Recruiting
EASi-PROTKTโ„ข - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
Boehringer Ingelheim
Phase 3
11,800
Baotou, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dalian
2025-07-22
Recruiting
A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors
NCT07083323Advanced Solid Tumor
Sichuan Huiyu Pharmaceutical Co., Ltd
Phase 1/2
262
Beijing
2025-07-22
Recruiting
MRgLITT for mTLE: A PROBE Trial
NCT06720922Temporal Lobe Epilepsy (TLE)
Beijing Tiantan Hospital
Not applicable
120
Beijing
2025-07-21
Recruiting
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
NCT07060807Breast Neoplasms
Merck Sharp & Dohme LLC
Phase 3
1,000
Hefei, Beijing, Chongqing, Wanzhou, Fujian, Guangzhou, Jiangmen, Nanning
2025-07-21
By invitation
Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer๏ผˆUPGRADE-TNBC๏ผ‰
NCT06910072Triple-Negative Breast Cancer (TNBC), Neoadjuvant Therapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2/3
32
Beijing
2025-07-21
Recruiting
A Phase I/โ…ก Human Study of HY0001a for Injection in Adult Participants With Advanced Solid Tumors
NCT07069062Solid Tumor
Sichuan Huiyu Pharmaceutical Co., Ltd
Phase 1/2
261
Beijing
2025-07-21
By invitation
Exploratory Trial of VR Intervention on Neuroplasticity in Older Adults With Cognitive Frailty
NCT07183033Cognitive Frailty
Peking Union Medical College
Not applicable
15
Beijing
2025-07-21
Recruiting
The Efficacy and Safety Assessment of Allogeneic ฮณฮด T Cells in Patients With MRD-positive AML After Allo-HSCT
NCT07126782AML (Acute Myelogenous Leukemia), AML
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1
10
Beijing
2025-07-20
Recruiting
REFINE-HCM: Intramyocardial Septal Radiofrequency Ablation for Obstructive Hypertrophic Cardiomyopathy
NCT07006493Hypertrophic Cardiomyopathy, Obstructive
SuZhou Sinus Medical Technologies Co.,Ltd
Not applicable
124
Beijing, Hangzhou
2025-07-20
Not yet open
Efficacy and Safety of AK112 Combined Chemotherapy as Neoadjuvant Treatment for Signet Ring Cell-containing G/GEJ Adenocarcinoma
NCT07091227Gastric or Gastroesophageal Junction Adenocarcinoma
Peking Union Medical College Hospital
Phase 2
66
Beijing
2025-07-20
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of Tacabrutideg (BGB-16673) in Adults With Chronic Spontaneous Urticaria and in Healthy Participants
NCT07005713Chronic Spontaneous Urticaria
BeOne Medicines
Phase 1
58
Beijing, Chongqing, Guangzhou, Wuhan, Changsha, Qingdao, Chengdu, Hangzhou
2025-07-19
Recruiting
Early Prophylactic Decompressive Hemicraniectomy Following Endovascular Therapy in Large Hemispheric Infarct Trial
NCT07118345Stroke, Ischemic, Cerebral Edema
Xuanwu Hospital, Beijing
Not applicable
380
Beijing, Shandong
2025-07-19
Recruiting
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
NCT06824168Acute Myeloid Leukemia, Leukemia
Daiichi Sankyo
Phase 2
130
Beijing, Changchun, Guangzhou, Hangzhou, Nanchang, Nanjing, Nanning, Qingdao
2025-07-18
Active, closed
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
NCT06468033Primary Myelofibrosis, Myeloproliferative Neoplasm
PharmaEssentia
Phase 3
160
Beijing, Chongqing, Guangdong, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing
2025-07-18
Recruiting
A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy
NCT07071337Metastatic Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
430
Beijing, Guangzhou
2025-07-18
Recruiting
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
NCT06929273Bipolar Disorder Type I With Mania
Bristol-Myers Squibb
Phase 3
450
Beijing, Guangzhou, Baoding, Changsha, Nanjing, Xi'an, Chengdu, Tianjin
2025-07-18
Recruiting
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
NCT06953089Solid Tumors
DualityBio Inc.
Phase 2
450
Beijing, Dongguan, Henan, Xinxiang, Hubei, Wuhan, Changsha, Xuzhou
2025-07-18
Recruiting
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
NCT07069712Gastroesophageal Adenocarcinoma
AstraZeneca
Phase 2
100
Beijing, Changchun, Changzhi, Chengdu, Fuzhou, Hangzhou, Kunming, Qingdao
2025-07-17
Recruiting
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
NCT06997497Colon Adenocarcinoma, Rectal Adenocarcinoma
Merck Sharp & Dohme LLC
Phase 3
477
Hefei, Beijing, Chongqing, Wanzhou, Fuzhou, Xiamen, Guangzhou, Shenzhen
2025-07-16
By invitation
A Study of Cizutamig in Patients With Immunoglobulin A Nephropathy
NCT07135219Immunoglobulin A Nephropathy (IgAN)
Peking University First Hospital
Phase EARLY_PHASE1
15
Beijing
2025-07-16
Recruiting
Real-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients
NCT07296627Newly Diagnosed Multiple Myeloma (NDMM)
Peking University People's Hospital
Observational
500
Beijing
2025-07-16
Recruiting
Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT07039669Pulmonary Disease, Chronic Obstructive (COPD)
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 3
594
Beijing, Shenzhen, Nanjing, Hangzhou
2025-07-16
Not yet open
A Study to Predict Recompensation in Patients With Decompensated Cirrhosis Using Spleen Stiffness and Simple Blood Tests
NCT07087041Decompensated Cirrhosis, Hepatitis B Virus (HBV) Infection, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Alcohol-Related Liver Disease
Beijing Friendship Hospital
Observational
735
Beijing, Fuzhou, Lanzhou, Foshan, Guangzhou, Zhuhai, Guiyang, Shiyan
2025-07-15
Recruiting
A Clinical Trial Evaluating Injection of TQB6411 in Subjects With Advanced Malignant Tumors
NCT07043751Advanced Malignant Tumors
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
216
Beijing, Dongguan, Guangdong, Guangzhou, Anyang, Zhengzhou, Wuhan, Changsha
2025-07-15
Active, closed
A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)
NCT06963710Chronic Hepatitis B Infection
Aligos Therapeutics
Phase 2
200
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Nanjing, Shanghai
2025-07-15
Not yet open
Calcium Channel Blocker Amlodipine for Endometrial Cancer Therapy
NCT06942377Endometrial Cancer
Peking University People's Hospital
Phase 2
140
Beijing
2025-07-15
Not yet open
The Phase Ib Clinical Trial of the XH-S004 Tablet in Patients With Chronic Obstructive Pulmonary Disease (COPD) to Evaluate Its Safety, Tolerability, Pharmacokinetic Characteristics and Pharmacodynamic Characteristics After Multiple Administrations
NCT07035652Chronic Obstructive Pulmonary Disease (COPD)
S-INFINITY Pharmaceuticals Co., Ltd
Phase 1
81
Beijing
2025-07-15
Recruiting
Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy
NCT06924606Advanced NSCLC
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
66
Beijing, Jilin City, Hunan, Sichuan, Chongqing, Guangdong, Heilongjiang, Anyang
2025-07-15
Recruiting
A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
NCT06963827Kidney Disease
Takeda
Phase 3
347
Beijing, Changping, Xiamen, Guangzhou, Shenzhen, Changsha, Baotou, Nanjing
2025-07-15
By invitation
Spontaneous Breathing Mode: A Risk for Hypoxemia During OLV?
NCT07494006Lung Cancer, OLV, Hypoxemia During Surgery
Peking University People's Hospital
Observational
44
Beijing
2025-07-15
Recruiting
Efficacy and Safety of Surgical Treatment for Type IVa CBD
NCT07036848Choledochal Cyst
Beijing Tsinghua Chang Gung Hospital
Observational
1,500
Beijing
2025-07-14
Recruiting
Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment
NCT07559864GIST - Gastrointestinal Stromal Tumor, KIT Gene Mutation
Jian Li
Phase 2
100
Beijing
2025-07-14
Recruiting
Planned Delivery at 37 Versus 36 Weeks in Pregnancies With Placenta Previaand Accreta
NCT07025954Placenta Previa, Placenta Accreta Spectrum, Antepartum Bleeding, Emergency Cesarean Section
The Third Affiliated Hospital of Guangzhou Medical University
Not applicable
600
Guangzhou, Zhengzhou, Chengdu, Beijing, Chongqing
2025-07-12
Active, closed
Efficacy of Rescue Stenting/Angioplasty After Failed Thrombectomy for Acute Large Intracranial Vascular Occlusion
NCT07026344Acute Ischemic Stroke
Beijing Anzhen Hospital
Not applicable
312
Beijing
2025-07-12
Active, closed
Telitacicept for PGNMID: A Single-Arm Study
NCT07111338Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits
Peking University First Hospital
Phase 2
10
Beijing
2025-07-12
Recruiting
Study of GV20-0251 in Participants With Solid Tumor Malignancies
NCT07070518Solid Tumor Cancer, Adult Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma
GV20 Therapeutics
Phase 1/2
350
Beijing, Shanghai
2025-07-11
Recruiting
This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab
NCT06862206Chronic Obstructive Pulmonary Disease
AstraZeneca
Observational
1,000
Anhui, Anning, Beijing, Binzhou, Changzhou, Fenyang, Guangdong, Guangzhou
2025-07-11
Recruiting
Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell Carcinoma
NCT07097935Advanced Clear Cell Renal Cell Carcinoma
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1/2
104
Beijing
2025-07-10
Recruiting
A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors
NCT06953323Advanced Solid Tumor
Wigen Biomedicine Technology (Shanghai) Co., Ltd.
Phase 1/2
86
Beijing, Fuzhou, Guangzhou, Nanning, Wuhan, Changsha, Shenyang, Hangzhou
2025-07-10
By invitation
HS-IT101 Injection in the Treatment of Advanced Melanoma
NCT06941818Advanced Melanoma
Qingdao Sino-Cell Biomedicine Co., Ltd.
Phase 1
10
Beijing
2025-07-10
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
NCT07011732Alzheimer Disease
Bristol-Myers Squibb
Phase 3
426
Beijing, Haidian District, Chongqing, Guangzhou, Shenzhen, Changsha, Nanjing, Shanghai
2025-07-10
Recruiting
Study on the Safety and Efficacy of Domestic Single-Port Robot-Assisted Metabolic Bariatric Surgery.
NCT07335731Obesity, Robot Surgery
China-Japan Friendship Hospital
Not applicable
50
Beijing
2025-07-10
Recruiting
Application of the CD73-Targeted Probe โถโธGa-DOTA-mPNE PET/CT Imaging in the Diagnosis of Malignant Tumors
NCT07023640Malignant Neoplasms of Brain
Peking Union Medical College Hospital
Not applicable
50
Beijing
2025-07-10
Not yet open
Longitudinal Observational Study on Immune Thrombocytopenia
NCT07068425Immune Thrombocytopenia (ITP)
Peking University People's Hospital
Observational
2,000
Beijing
2025-07-10
Recruiting
Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC
NCT07186621Hepatocellular Carcinoma (HCC), Radiotherapy, Adjuvant, Immune Checkpoint Inhibitor, TACE
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3
286
Beijing
2025-07-10
Recruiting
A Clinical Trial of HRS-7058 Combined Anti-tumor Drugs in Subjects With Solid Tumors
NCT07032077Solid Tumors
Shandong Suncadia Medicine Co., Ltd.
Phase 2
100
Beijing
2025-07-09
Recruiting
A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies
NCT07070323T-Cell Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia, T-cell Malignancies
Beijing GoBroad Hospital
Phase 1/2
54
Beijing, Shanghai, Chengdu
2025-07-09
Active, closed
A Study to Evaluate the Effectiveness and Safety of Restylane Skinboosters Vital Lidocaine
NCT07047638Skin Quality Improvement
Galderma R&D
Not applicable
171
Beijing
2025-07-09
Recruiting
Teneteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-โ…ฃ
NCT06414499Minor Ischemic Stroke
Beijing Tiantan Hospital
Phase 3
1,386
Beijing
2025-07-09
Recruiting
MITRIS China Post Market Clinical Follow-up (PMCF) Study
NCT07059793Mitral Valve Replacement
Edwards Lifesciences
Observational
250
Beijing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Nanjing, Xi'an, Jinan
2025-07-08
Recruiting
Endobronchial Silicone Valve for Patients With Emphysema
NCT07097896Emphysema
China-Japan Friendship Hospital
Not applicable
147
Beijing
2025-07-08
Recruiting
Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy
NCT07823049Pancreatic Cancer
Evopoint Biosciences Inc.
Phase 3
226
Shanghai, Beijing, Binzhou, Changsha, Changzhou, Chengdu, Chongqing, Fuyang
2025-07-08
Recruiting
QA108 Phase III Study in Subjects With Intermediate AMD
NCT07189169Intermediate Age-Related Macular Degeneration
Smilebiotek Zhuhai Limited
Phase 3
400
Beijing
2025-07-08
Recruiting
A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Patients With Hidradenitis Suppurativa
NCT06932003Hidradenitis Suppurativa (HS)
Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
Phase 1/2
12
Beijing
2025-07-08
Recruiting
Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer
NCT07008976Metastatic Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
246
Bengbu, Hefei, Beijing, Fuzhou, Lanzhou, Jiangmen, Nanning, Guiyang
2025-07-07
Recruiting
A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease
NCT07068165IgG4 Related Disease
Peking Union Medical College Hospital
Phase 2/3
198
Beijing
2025-07-07
Active, closed
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
NCT06991556Metastatic Hormone-sensitive Prostate Cancer
Novartis Pharmaceuticals
Phase 2
168
Beijing
2025-07-07
Recruiting
A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive
NCT06930794Non-Small Cell Lung Cancer
Beijing Pearl Biotechnology Limited Liability Company
Phase 3
300
Beijing, Guangzhou
2025-07-07
Recruiting
Interventions for Silent Brain Infarction and Perioperative Neurocognitive Disorders in Cardiovascular Surgery
NCT07048002Silent Brain Infarction, Neurocognitive Disorders, Cardiac Surgery, Neuroprotective
Chinese Academy of Medical Sciences, Fuwai Hospital
Not applicable
912
Beijing, Wuhan
2025-07-06
Not yet open
AI-Driven Early Warning System for Perioperative Risks in Acute Hemorrhagic Stroke
NCT06998082Acute Hemorrhagic Stroke
Beijing Tiantan Hospital
Observational
1,533
Beijing
2025-07-06
Recruiting
A Clinical Study to Evaluate the Long-term Safety of HRS-1893 in Hypertrophic Cardiomyopathy
NCT07021963Hypertrophic Cardiomyopathy
Shandong Suncadia Medicine Co., Ltd.
Phase 2
300
Beijing
2025-07-04
Recruiting
ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Craniopharyngioma Patients
NCT07177482Craniopharyngioma
Deling Li
Not applicable
20
Beijing
2025-07-04
Active, closed
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis
NCT07483450Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Hoffmann-La Roche
Phase 4
60
Nanchang, Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Hohhot
2025-07-04
Active, closed
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT07047118Prostatic Cancer, Castration-Resistant
Novartis Pharmaceuticals
Phase 2
138
Beijing
2025-07-03
Recruiting
Effect of Balloon Angioplasty vs Stenting Following Residual Stenosis After Endovascular Treatment of Intracranial Atherosclerotic Acute Ischemic Stroke
NCT07026331Acute Ischemic Stroke, Intracranial Atherosclerosis ICAS
Beijing Anzhen Hospital
Not applicable
486
Beijing
2025-07-03
Recruiting
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
NCT06859762Advanced Solid Tumor
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
630
Beijing, Guangzhou, Harbin, Nanchang, Shenyang, Jinan, Shanghai, Tianjin
2025-07-02
Recruiting
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
NCT07177352Alzheimers Disease
Hoffmann-La Roche
Phase 3
80,000
Beijing, Xuzhou, Changchun, Chengdu, Chongqing, Guangzhou, Hefei, Nanjing
2025-07-02
Not yet open
Efficacy and Safety of Rituximab in the Treatment of Anti-Vimentin Antibody-associated Diseases
NCT07051070Anti-Vimentin Antibody-associated Diseases, Meningoencephalomyelitis Associated With Vimentin IgG Autoantibodies
Xuanwu Hospital, Beijing
Phase 4
40
Beijing
2025-07-01
Recruiting
Safety and Efficacy of Universal CD19-targeting CAR-ฮณฮดT Cells in Refractory Autoimmune Diseases
NCT06828042Systemic Lupus Erthematosus, Systemic Sclerosis (SSc), Sjogren Syndrome, ANCA Associated Vasculitis (AAV)
Peking University Third Hospital
Phase 1/2
9
Beijing
2025-07-01
Recruiting
Safety and Efficacy of Ventricular Irrigation for Ventriculitis
NCT06358209Central Nervous System Infections
RenJi Hospital
Not applicable
310
Hefei, Wuhu, Beijing, Fuzhou, Guangzhou, Shenzhen, Zhongshan, Harbin
2025-07-01
Recruiting
Rectal NSAIDs With/Without PD Stent for PEP Prevention
NCT07117318Post-ERCP Acute Pancreatitis, Non-steroid Anti-inflammatory Drugs, Pancreatic Duct Stent Placement
Air Force Military Medical University, China
Not applicable
1,278
Beijing, Chongqing, Xiamen, Harbin, Kaifeng, Wuhan, Changsha, Xi'an
2025-07-01
By invitation
68Ga-NYM096 PET/ CT for the Detection of Clear Cell Renal Cell Carcinoma in Presurgical Patients With Renal Masses
NCT07101900Clear Cell Renal Cell Carcinoma
Peking Union Medical College Hospital
Phase 2
100
Beijing
2025-07-01
Not yet open
Iguratimod Plus Low-dose Rituximab vs Low-dose Rituximab in Corticosteroid-resistant or Relapsed ITP
NCT07057778Immune Thrombocytopenia (ITP)
Peking University People's Hospital
Phase 2
120
Beijing
2025-07-01
Recruiting
Safety and Efficacy of Oral HX9428 Tablets in Subjects With Wet Age-related Macular Degeneration (wAMD)
NCT07185841Wet Age-related Macular Degeneration (AMD)
Fujian Haixi Pharmaceuticals Co., Ltd.
Phase 1/2
198
Beijing
2025-07-01
Not yet open
Evaluating AI and Human Expert Decisions in Colorectal Cancer
NCT07045207Colorectal Cancer
Peking University Cancer Hospital & Institute
Observational
1,500
Beijing
2025-07-01
Not yet open
JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma
NCT07024147B-Cell Non-Hodgkin Lymphoma, Large B Cell Diffuse Lymphoma, Follicular Lymphoma, Marginal Zone B Cell Lymphoma
Peking University Cancer Hospital & Institute
Phase 1
20
Beijing
2025-07-01
Recruiting
Association of Genetic Variants With Myopia
NCT07030153Myopia
Beijing Visionly Plus Eye Hospital
Observational
1,000
Beijing
2025-07-01
Recruiting
Effects and Mechanisms of Temporal Interference Brain Stimulation on Memory Function in Preclinical Alzheimer's Disease
NCT07031687Alzheimer Disease
Xuanwu Hospital, Beijing
Not applicable
1,200
Sanya, Beijing
2025-07-01
Rows per page Showing 1901–2000 of 5484
Previous 18 19 20 21 22 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 23 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing?page=20

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 5,484 of those studies with a site in Beijing.

How many clinical trials are recruiting in Beijing?

3,341 of the 5,484 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 966 have not yet opened recruitment, 1,001 are active but closed to new participants, and 176 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.